Alistair Irvine

Alistair Irvine serves as the Founding Chief Executive Officer at Scarlet Therapeutics Ltd since August 2022 and as Managing Director at Epigenics GmbH since April 2022. Previously, Alistair held the role of Chief Business Officer at Kuros Biosciences from January 2014 to February 2023, where significant contributions included leading the due diligence for a CHF30M acquisition and streamlining development efforts through commercial evaluation. Alistair also served as Director of Business Development at Kuros Biosurgery AG from 2006 to December 2013, managing various projects and negotiations. Earlier experience includes positions at ML Laboratories plc, Cobra Therapeutics Ltd, and Therexsys Ltd, focusing on research, development of gene expression technologies, and immunotherapy. Alistair holds a BSc(Hons) in Biochemistry from The University of Edinburgh and a PhD in Molecular Biology from The University of Sheffield.